PharmacoEconomics & Outcomes News 792, p26 - 2 Dec 2017
Rotavirus vaccine potentially
cost effective in Afghanistan
Introduction of a rotavirus vaccination programme is
likely to be cost effective in Afghanistan, according to
findings of a study published in Vaccine.
The ProVac Initiative UNIVAC model was used to
evaluate the potential impact and cost effectiveness of a
national rotavirus immunization programme with a two-
dose schedule of Rotarix (RIX 4414) in ten birth cohorts
in Afghanistan between 2017 and 2026, compared with
no rotavirus vaccination, from government and societal
perspectives, with and without Gavi (Vaccine Alliance)
support. The assumed vaccine price was $2.02
Over the 10-year period, rotavirus vaccination was
predicted to avert over one million cases of rotavirus
infection, and approximately 660 000 outpatient visits,
50 000 rotavirus-related hospital admissions,
650 000 disability-adjusted life-years (DALYs) and
12 000 deaths. It would save $1.35 million in treatment
costs from the government perspective and
$2.80 million from a societal perspective.
Without the Gavi subsidy, the estimated incremental
cost-effectiveness ratio (ICER) for rotavirus vaccination
versus no vaccination was $82 per DALY averted from
the government perspective and $80 per DALY averted
from the societal perspective. With the Gavi subsidy,
ICERs were $31 and $29 per DALY averted, respectively.
It was estimated that the annual cost of the rotavirus
vaccination programme would account for 2.8% of the
total immunisation budget and 0.1% of total health
expenditure in Afghanistan in 2017.
"In summary, this analysis demonstrates that rotavirus
vaccination is likely to be highly cost-effective and avert
a substantial health and economic burden of disease in
Afghanistan," said the authors.
* 2017 US dollars
Anwari P, et al. Potential impact and cost-effectiveness of rotavirus vaccination in
Afghanistan. Vaccine : 26 Oct 2017. Available from: URL: http://doi.org/10.1016/
PharmacoEconomics & Outcomes News 2 Dec 2017 No. 7921173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved